LivaNova PLC - Ordinary Shares (LIVN): Price and Financial Metrics

LivaNova PLC - Ordinary Shares (LIVN): $50.76

0.16 (+0.32%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

LIVN Price/Volume Stats

Current price $50.76 52-week high $59.86
Prev. close $50.60 52-week low $41.44
Day low $49.70 Volume 576,700
Day high $50.84 Avg. volume 592,760
50-day MA $51.60 Dividend yield N/A
200-day MA $51.28 Market Cap 2.74B

LIVN Stock Price Chart Interactive Chart >

LIVN POWR Grades

  • LIVN scores best on the Growth dimension, with a Growth rank ahead of 82.44% of US stocks.
  • The strongest trend for LIVN is in Growth, which has been heading down over the past 26 weeks.
  • LIVN ranks lowest in Momentum; there it ranks in the 24th percentile.

LIVN Stock Summary

  • With a price/earnings ratio of 926.77, LIVANOVA PLC P/E ratio is greater than that of about 99.32% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for LIVANOVA PLC is higher than 95.45% of stocks in our set with a positive cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, LIVANOVA PLC is reporting a growth rate of -262.31%; that's higher than merely 4.77% of US stocks.
  • If you're looking for stocks that are quantitatively similar to LIVANOVA PLC, a group of peers worth examining would be VRNT, VIAV, YOU, IFF, and WDAY.
  • LIVN's SEC filings can be seen here. And to visit LIVANOVA PLC's official web site, go to www.livanova.com.

LIVN Valuation Summary

  • In comparison to the median Healthcare stock, LIVN's price/sales ratio is 13.64% higher, now standing at 2.5.
  • LIVN's price/earnings ratio has moved up 898.9 over the prior 100 months.

Below are key valuation metrics over time for LIVN.

Stock Date P/S P/B P/E EV/EBIT
LIVN 2023-12-29 2.5 2.3 971.9 37.8
LIVN 2023-12-28 2.5 2.3 985.6 38.3
LIVN 2023-12-27 2.5 2.3 980.5 38.1
LIVN 2023-12-26 2.5 2.3 974.3 37.8
LIVN 2023-12-22 2.5 2.3 972.6 37.8
LIVN 2023-12-21 2.5 2.3 973.4 37.8

LIVN Growth Metrics

    Its 2 year price growth rate is now at 40.38%.
  • The 5 year net cashflow from operations growth rate now stands at -275.07%.
  • Its 2 year revenue growth rate is now at -4.45%.
LIVN's revenue has moved down $67,175,000 over the prior 33 months.

The table below shows LIVN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1,016.995 84.698 -96.472
2022-06-30 1,017.605 73.013 -31.365
2022-03-31 1,027.937 108.887 -103.127
2021-12-31 1,035.365 102.544 -135.818
2021-09-30 1,034.856 106.049 -407.079
2021-06-30 1,021.724 90.753 -379.614

LIVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LIVN has a Quality Grade of C, ranking ahead of 45.21% of graded US stocks.
  • LIVN's asset turnover comes in at 0.441 -- ranking 110th of 186 Medical Equipment stocks.
  • XRAY, PDEX, and ZBH are the stocks whose asset turnover ratios are most correlated with LIVN.

The table below shows LIVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.441 0.662 -0.416
2021-06-30 0.421 0.653 -0.308
2021-03-31 0.383 0.654 -0.262
2020-12-31 0.378 0.662 -0.271
2020-09-30 0.385 0.683 -0.167
2020-06-30 0.397 0.690 -0.156

LIVN Price Target

For more insight on analysts targets of LIVN, see our LIVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $100.71 Average Broker Recommendation 1.43 (Moderate Buy)

LivaNova PLC - Ordinary Shares (LIVN) Company Bio


LivaNova PLC. offers cardiac surgery, cardiac rhythm management, and neuromodulation related products worldwide. The company was founded in 1987 and is based in London, England.


LIVN Latest News Stream


Event/Time News Detail
Loading, please wait...

LIVN Latest Social Stream


Loading social stream, please wait...

View Full LIVN Social Stream

Latest LIVN News From Around the Web

Below are the latest news stories about LIVANOVA PLC that investors may wish to consider to help them evaluate LIVN as an investment opportunity.

Is Now The Time To Look At Buying LivaNova PLC (NASDAQ:LIVN)?

While LivaNova PLC ( NASDAQ:LIVN ) might not be the most widely known stock at the moment, it received a lot of...

Yahoo | December 11, 2023

Billionaire David Einhorn’s 10 Stock Picks with Huge Upside Potential

In this article, we will take a look at billionaire David Einhorn’s 10 stock picks with huge upside potential. To skip our analysis of David Einhorn’s investment strategy and Greenlight Capital’s previous performance, you can go directly to see the Billionaire David Einhorn’s 5 Stock Picks with Huge Upside Potential. David Einhorn is a renowned […]

Yahoo | December 5, 2023

LivaNova warns cybersecurity incident disrupts systems, takes steps to limit impact

The medical device maker warned that the incident is expected to continue to disrupt its business operations.

Yahoo | November 27, 2023

15 Stocks Billionaire David Einhorn Just Bought and Sold

In this article, we will take a look at the 15 stocks billionaire David Einhorn just bought and sold. To see more such companies, go directly to 5 Stocks Billionaire David Einhorn Just Bought and Sold. David Einhorn is a notable American hedge fund manager who is known for beating the stock market for a […]

Yahoo | November 24, 2023

A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)

Key Insights The projected fair value for LivaNova is US$44.38 based on 2 Stage Free Cash Flow to Equity LivaNova's...

Yahoo | November 24, 2023

Read More 'LIVN' Stories Here

LIVN Price Returns

1-mo 1.76%
3-mo 1.93%
6-mo -9.02%
1-year 16.40%
3-year -33.66%
5-year -48.32%
YTD -1.89%
2023 -6.84%
2022 -36.47%
2021 32.05%
2020 -12.22%
2019 -17.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!